QQQ   269.75 (-0.21%)
AAPL   446.59 (-0.96%)
MSFT   207.33 (-0.44%)
FB   264.91 (+0.72%)
GOOGL   1,506.14 (+0.62%)
AMZN   3,141.60 (-0.21%)
NVDA   441.17 (-1.22%)
CGC   17.64 (-1.62%)
BABA   251.86 (+1.50%)
TSLA   1,407.30 (-0.79%)
GE   6.79 (+1.80%)
MU   48.85 (-0.61%)
AMD   78.93 (-4.03%)
T   30.38 (+0.60%)
F   7.29 (+2.82%)
ACB   10.09 (-1.27%)
GILD   68.30 (-0.32%)
NFLX   474.92 (-1.75%)
DIS   131.37 (+2.00%)
BAC   27.42 (+3.24%)
BA   185.38 (+3.33%)
QQQ   269.75 (-0.21%)
AAPL   446.59 (-0.96%)
MSFT   207.33 (-0.44%)
FB   264.91 (+0.72%)
GOOGL   1,506.14 (+0.62%)
AMZN   3,141.60 (-0.21%)
NVDA   441.17 (-1.22%)
CGC   17.64 (-1.62%)
BABA   251.86 (+1.50%)
TSLA   1,407.30 (-0.79%)
GE   6.79 (+1.80%)
MU   48.85 (-0.61%)
AMD   78.93 (-4.03%)
T   30.38 (+0.60%)
F   7.29 (+2.82%)
ACB   10.09 (-1.27%)
GILD   68.30 (-0.32%)
NFLX   474.92 (-1.75%)
DIS   131.37 (+2.00%)
BAC   27.42 (+3.24%)
BA   185.38 (+3.33%)
QQQ   269.75 (-0.21%)
AAPL   446.59 (-0.96%)
MSFT   207.33 (-0.44%)
FB   264.91 (+0.72%)
GOOGL   1,506.14 (+0.62%)
AMZN   3,141.60 (-0.21%)
NVDA   441.17 (-1.22%)
CGC   17.64 (-1.62%)
BABA   251.86 (+1.50%)
TSLA   1,407.30 (-0.79%)
GE   6.79 (+1.80%)
MU   48.85 (-0.61%)
AMD   78.93 (-4.03%)
T   30.38 (+0.60%)
F   7.29 (+2.82%)
ACB   10.09 (-1.27%)
GILD   68.30 (-0.32%)
NFLX   474.92 (-1.75%)
DIS   131.37 (+2.00%)
BAC   27.42 (+3.24%)
BA   185.38 (+3.33%)
QQQ   269.75 (-0.21%)
AAPL   446.59 (-0.96%)
MSFT   207.33 (-0.44%)
FB   264.91 (+0.72%)
GOOGL   1,506.14 (+0.62%)
AMZN   3,141.60 (-0.21%)
NVDA   441.17 (-1.22%)
CGC   17.64 (-1.62%)
BABA   251.86 (+1.50%)
TSLA   1,407.30 (-0.79%)
GE   6.79 (+1.80%)
MU   48.85 (-0.61%)
AMD   78.93 (-4.03%)
T   30.38 (+0.60%)
F   7.29 (+2.82%)
ACB   10.09 (-1.27%)
GILD   68.30 (-0.32%)
NFLX   474.92 (-1.75%)
DIS   131.37 (+2.00%)
BAC   27.42 (+3.24%)
BA   185.38 (+3.33%)
Log in

OTCMKTS:MATNMateon Therapeutics Stock Price, Forecast & News

$0.21
-0.02 (-6.82 %)
(As of 08/11/2020 01:10 PM ET)
Add
Compare
Today's Range
$0.20
Now: $0.21
$0.22
50-Day Range
$0.17
MA: $0.21
$0.29
52-Week Range
$0.08
Now: $0.21
$0.35
Volume215,538 shs
Average Volume460,997 shs
Market Capitalization$18.16 million
P/E RatioN/A
Dividend YieldN/A
Beta1.95
Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical, focuses on developing small molecule injectable drugs for the treatment of cancer. It is developing CA4P, an immuno-oncology agent that stimulates the immune system against the tumor; and OXi4503 for the treatment of relapsed/refractory acute myeloid leukemia. The company was formerly known as OXiGENE, Inc. and changed its name to Mateon Therapeutics, Inc. in June 2016. Mateon Therapeutics, Inc. was founded in 1988 and is headquartered in South San Francisco, California.
Read More
Mateon Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.72 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MATN
Previous SymbolNASDAQ:MATN
CUSIPN/A
Phone650-635-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.20 per share

Profitability

Net Income$-6,640,000.00

Miscellaneous

Employees2
Market Cap$18.16 million
Next Earnings Date8/17/2020 (Estimated)
OptionableNot Optionable
$0.21
-0.02 (-6.82 %)
(As of 08/11/2020 01:10 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MATN News and Ratings via Email

Sign-up to receive the latest news and ratings for MATN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Mateon Therapeutics (OTCMKTS:MATN) Frequently Asked Questions

How has Mateon Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Mateon Therapeutics' stock was trading at $0.1210 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MATN stock has increased by 69.4% and is now trading at $0.2050.
View which stocks have been most impacted by COVID-19
.

When is Mateon Therapeutics' next earnings date?

Mateon Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 17th 2020.
View our earnings forecast for Mateon Therapeutics
.

How were Mateon Therapeutics' earnings last quarter?

Mateon Therapeutics Inc (OTCMKTS:MATN) announced its earnings results on Wednesday, May, 15th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, meeting the Zacks' consensus estimate of ($0.02).
View Mateon Therapeutics' earnings history
.

Has Mateon Therapeutics been receiving favorable news coverage?

Media coverage about MATN stock has been trending neutral recently, according to InfoTrie. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Mateon Therapeutics earned a daily sentiment score of 0.2 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
View the latest news about Mateon Therapeutics
.

Are investors shorting Mateon Therapeutics?

Mateon Therapeutics saw a increase in short interest in February. As of February 15th, there was short interest totaling 43,600 shares, an increase of 8,620.0% from the January 31st total of 500 shares. Based on an average daily trading volume, of 59,900 shares, the short-interest ratio is presently 0.7 days.
View Mateon Therapeutics' Short Interest
.

Who are some of Mateon Therapeutics' key competitors?

What other stocks do shareholders of Mateon Therapeutics own?

Who are Mateon Therapeutics' key executives?

Mateon Therapeutics' management team includes the following people:
  • Dr. William D. Schwieterman, Chairman, CEO & Pres (Age 61)
  • Mr. Matthew M. Loar, Chief Financial Officer (Age 56)
  • Ms. Shari Annes, Exec. Officer of Investor Relations
  • Dr. Yuval Binur, Exec. VP of Financial
  • Ms. Pamela Ha, Controller

What is Mateon Therapeutics' stock symbol?

Mateon Therapeutics trades on the OTCMKTS under the ticker symbol "MATN."

How do I buy shares of Mateon Therapeutics?

Shares of MATN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mateon Therapeutics' stock price today?

One share of MATN stock can currently be purchased for approximately $0.21.

How big of a company is Mateon Therapeutics?

Mateon Therapeutics has a market capitalization of $18.16 million. Mateon Therapeutics employs 2 workers across the globe.

What is Mateon Therapeutics' official website?

The official website for Mateon Therapeutics is www.oncotelic.com.

How can I contact Mateon Therapeutics?

Mateon Therapeutics' mailing address is 29397 AGOURA ROAD SUITE 107, AGOURA HILLS CA, 91301. The biopharmaceutical company can be reached via phone at 650-635-7000 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.